Sarepta Therapeutics,, Inc. Common Stock (SRPT) Stock Price

SRPTStock

$17.10−26.74%52W

Market Cap$1.81B

P/E7.77x

PEG Ratio-0.09

Div yield—

Beta0.47

SRPT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-32.70%

Price vs S&P 500 (4W)-13.77%

PEG Ratio-0.09

VGM Score53.14

P/E Ratio (Annual)7.77x

Book Value / Share (Quarterly)$14.46

P/TBV (Annual)2.03x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)33.07%

Cash Flow / Share (Quarterly)$0.71

Price vs S&P 500 (YTD)-32.47%

Gross Margin (TTM)67.47%

Net Profit Margin (TTM)-6.93%

EPS (TTM)$-1.82

10-Day Avg Trading Volume3.79M

EPS Excl Extra (TTM)$-1.82

Revenue Growth (5Y)32.41%

EPS (Annual)$-7.13

ROI (Annual)-36.22%

Gross Margin (Annual)69.33%

Net Profit Margin (5Y Avg)-39.65%

Cash / Share (Quarterly)$7.47

P/E Basic Excl Extra (TTM)27.89x

Revenue Growth QoQ (YoY)-34.34%

P/E Normalized (Annual)7.77x

ROA (Last FY)-21.30%

Revenue Growth TTM (YoY)-20.44%

EBITD / Share (TTM)$-1.14

ROE (5Y Avg)-67.48%

Operating Margin (TTM)-6.40%

Cash Flow / Share (Annual)$-3.00

P/B Ratio1.18x

P/B Ratio (Quarterly)1.24x

Net Income / Employee (Annual)$-854,400

EV / Revenue (TTM)1.05x

Net Interest Coverage (TTM)-29.15x

ROA (TTM)-4.14%

EV / EBITDA (TTM)1353.28x

EPS Incl Extra (Annual)$-7.13

Current Ratio (Annual)2.32x

Quick Ratio (Quarterly)2.57x

3-Month Avg Trading Volume3.31M

52-Week Price Return-26.74%

P/E Incl Extra (TTM)27.89x

Revenue / Employee (TTM)$2,364,500

Tangible BV / Share (Quarterly)$14.17

P/S Ratio (Annual)0.82x

Asset Turnover (Annual)0.66x

52-Week High$24.68

Operating Margin (5Y Avg)-37.86%

EPS Excl Extra (Annual)$-7.13

CapEx CAGR (5Y)5.09%

Tangible BV CAGR (5Y)8.24%

26-Week Price Return-22.80%

Quick Ratio (Annual)1.44x

13-Week Price Return-0.70%

Total Debt / Equity (Annual)0.73x

Current Ratio (Quarterly)4.42x

Enterprise Value$2.08B

Revenue / Share Growth (5Y)25.96%

Asset Turnover (TTM)0.60x

Book Value / Share Growth (5Y)2.52%

Revenue / Employee (Annual)$2,632,600

Inventory Turnover (Annual)0.81x

Pretax Margin (Annual)-31.94%

Cash / Share (Annual)$8.95

3-Month Return Std Dev61.56%

Gross Margin (5Y Avg)82.32%

Net Income / Employee (TTM)$-163,700

ROE (Last FY)-62.55%

Net Interest Coverage (Annual)2.14x

EPS Basic Excl Extra (Annual)$-7.13

P/FCF (TTM)5.57x

Receivables Turnover (TTM)4.37x

EV / Free Cash Flow (TTM)27.62x

Total Debt / Equity (Quarterly)0.55x

EPS Incl Extra (TTM)$-1.82

Receivables Turnover (Annual)4.40x

ROI (TTM)-6.05%

P/S Ratio (TTM)0.91x

Pretax Margin (5Y Avg)-38.74%

Revenue / Share (Annual)$21.96

Tangible BV / Share (Annual)$10.59

Forward P/E15.79x

Price vs S&P 500 (52W)-42.27%

P/E Ratio (TTM)27.89x

Year-to-Date Return-20.54%

5-Day Price Return-1.95%

EPS Normalized (Annual)$-7.13

ROA (5Y Avg)-13.51%

Net Profit Margin (Annual)-32.45%

Month-to-Date Return-6.15%

Cash Flow / Share (TTM)$-7.32

EBITD / Share (Annual)$-6.79

Operating Margin (Annual)-31.07%

LT Debt / Equity (Annual)0.73x

P/CF (TTM)16.27x

ROI (5Y Avg)-22.02%

P/E Excl Extra (TTM)27.89x

LT Debt / Equity (Quarterly)0.55x

EPS Basic Excl Extra (TTM)$-1.82

P/TBV (Quarterly)1.27x

P/B Ratio (Annual)1.98x

Inventory Turnover (TTM)0.68x

Pretax Margin (TTM)-6.63%

Book Value / Share (Annual)$10.87

Price vs S&P 500 (13W)-3.38%

Beta0.47x

P/FCF (Annual)82.85x

Revenue / Share (TTM)$18.73

ROE (TTM)-9.96%

52-Week Low$14.68

vGradeC

gGradeC

mGradeB

vgmGradeC

SRPT Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	$0.49	$0.64	+31.67%(+$0.15)
Q1 2026	May 6, 2026	$1.05	$3.16	+202.07%(+$2.11)
Q4 2025	Feb 25, 2026	-$0.77	-$3.58	-365.29%(-$2.81)
Q3 2025	Nov 3, 2025	-$0.37	-$0.13	+65.03%(+$0.24)
Q2 2025	Aug 6, 2025	$1.16	$2.02	+73.90%(+$0.86)

SRPT Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.42

3.38

3.45

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
SRPTSarepta Therapeutics,, Inc. Common Stock	C	C	B	0.9x	-20.4%	67.5%	—	$17.10
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Sarepta Therapeutics,, Inc. Common Stock

Sarepta Therapeutics is a commercial-stage biopharmaceutical company specializing in RNA-targeted and gene therapies for rare neuromuscular disorders. The company has four FDA-approved treatments for Duchenne muscular dystrophy and maintains a pipeline of additional candidates for neuromuscular and other rare diseases. Its integrated business model encompasses discovery through patient delivery of genetic medicines for underserved patient populations.

SRPT Next Earnings Report

Report dateNov 4, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate$0.36

Revenue estimate$350.76M

Also reporting on Nov 4, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

Companies in Related Industries

TRLVTrulieve Cannabis Corp.Pharmaceutical Preparations
CCThe Chemours CompanyChemicals
RXRXRecursion Pharmaceuticals, Inc. Class A Common StockBiological Products
NVAXNovavax IncBiological Products
ALVOAlvotech Ordinary SharesBiological Products
OLNOlin Corp.Chemicals
MESOMesoblast Limited American Depositary SharesBiological Products
VIRVir Biotechnology, Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

3.5

Buy

Consensus rating

52-Week Range

Low$14.68

High$24.68